Neurocrine Biosciences Inc (1NBIX)

Currency in EUR
118.05
-14.90(-11.21%)
Closed·
1NBIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
118.05118.05
52 wk Range
94.70138.35
Key Statistics
Prev. Close
118.05
Open
118.05
Day's Range
118.05-118.05
52 wk Range
94.7-138.35
Volume
-
Average Volume (3m)
11
1-Year Change
-
Book Value / Share
25.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1NBIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Neurocrine Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Neurocrine Biosciences Inc Company Profile

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Employees
1800
Market
Italy

Compare 1NBIX to Peers and Sector

Metrics to compare
1NBIX
Peers
Sector
Relationship
P/E Ratio
35.9x−2.8x−0.6x
PEG Ratio
2.86−0.090.00
Price/Book
5.1x3.8x2.6x
Price / LTM Sales
5.7x33.4x3.3x
Upside (Analyst Target)
-558.3%41.8%
Fair Value Upside
Unlock53.1%6.2%Unlock

Earnings

Latest Release
Oct 28, 2025
EPS / Forecast
2.04 / --
Revenue / Forecast
794.90M / --
EPS Revisions
Last 90 days

1NBIX Income Statement

People Also Watch

43.44
EXEL
+0.02%
205.35
SNDK
-2.29%
253.37
ZBRA
+0.83%
66.54
HALO
-2.29%
64.45
DXCM
+1.46%

FAQ

What Stock Exchange Does Neurocrine Biosciences Inc Trade On?

Neurocrine Biosciences Inc is listed and trades on the Milan Stock Exchange stock exchange.

What Is the Stock Symbol for Neurocrine Biosciences Inc?

The stock symbol for Neurocrine Biosciences Inc is "1NBIX."

What Is the Neurocrine Biosciences Inc Market Cap?

As of today, Neurocrine Biosciences Inc market cap is 13.12B.

What Is Neurocrine Biosciences Inc's Earnings Per Share (TTM)?

The Neurocrine Biosciences Inc EPS (TTM) is 4.19.

From a Technical Analysis Perspective, Is 1NBIX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Neurocrine Biosciences Inc Stock Split?

Neurocrine Biosciences Inc has split 0 times.

How Many Employees Does Neurocrine Biosciences Inc Have?

Neurocrine Biosciences Inc has 1800 employees.

What is the current trading status of Neurocrine Biosciences Inc (1NBIX)?

As of 03 Dec 2025, Neurocrine Biosciences Inc (1NBIX) is trading at a price of 118.05, with a previous close of 118.05. The stock has fluctuated within a day range of 118.05 to 118.05, while its 52-week range spans from 94.70 to 138.35.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.